• Consensus Rating: Buy
  • Consensus Price Target: $75.43
  • Forecasted Upside: 28.78%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$58.57
▼ -1.22 (-2.04%)

This chart shows the closing price for ENOV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Enovis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ENOV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ENOV

Analyst Price Target is $75.43
▲ +28.78% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Enovis in the last 3 months. The average price target is $75.43, with a high forecast of $82.00 and a low forecast of $70.00. The average price target represents a 28.78% upside from the last price of $58.57.

This chart shows the closing price for ENOV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in Enovis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/17/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/15/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/13/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/13/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/12/2024

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$82.00Low
2/23/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$73.00 ➝ $79.00Low
2/23/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$73.00 ➝ $75.00Low
2/23/2024Needham & Company LLCBoost TargetBuy ➝ Buy$73.00 ➝ $82.00Low
2/13/2024StephensInitiated CoverageOverweight$72.00Low
1/22/2024UBS GroupInitiated CoverageBuy$75.00Low
1/8/2024Needham & Company LLCBoost TargetBuy ➝ Buy$70.00 ➝ $73.00Low
1/3/2024William BlairInitiated CoverageOutperformLow
12/20/2023Canaccord Genuity GroupBoost TargetBuy ➝ Buy$65.00 ➝ $71.00Low
12/15/2023Needham & Company LLCBoost TargetBuy ➝ Buy$62.00 ➝ $70.00Low
11/8/2023Needham & Company LLCLower TargetBuy ➝ Buy$70.00 ➝ $62.00Low
10/20/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$70.00Low
10/20/2023Roth MkmInitiated CoverageBuy$75.00Low
8/4/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$70.00Low
8/4/2023Robert W. BairdBoost TargetOutperform ➝ Outperform$67.00 ➝ $70.00Low
6/26/2023888Reiterated RatingInitiatesLow
6/26/2023Needham & Company LLCInitiated CoverageBuy$70.00Low
5/12/2023Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$55.00 ➝ $67.00Low
5/5/2023Robert W. BairdBoost Target$64.00 ➝ $67.00Low
3/28/2023Canaccord Genuity GroupReiterated RatingBuy$65.00Low
2/24/2023Robert W. BairdLower TargetOutperform$68.00 ➝ $64.00Low
1/3/2023Evercore ISIBoost Target$68.00Low
11/3/2022Robert W. BairdLower TargetOutperform$73.00 ➝ $68.00Low
10/26/2022Wells Fargo & CompanyLower TargetEqual Weight$60.00 ➝ $53.00Low
10/12/2022Jefferies Financial GroupInitiated CoverageBuy$60.00Low
10/11/2022The Goldman Sachs GroupInitiated CoverageBuy$57.00N/A
9/12/2022Canaccord Genuity GroupInitiated CoverageBuy$67.00Low
9/12/2022Evercore ISIInitiated CoverageOutperform$68.00Low
7/22/2022Wells Fargo & CompanyLower Target$60.00Low
6/28/2022ArgusInitiated CoverageHoldLow
6/27/2022Loop CapitalReiterated RatingBuy$68.00Low
6/16/2022Wells Fargo & CompanyInitiated CoverageEqual Weight$61.00High
5/11/2022Robert W. BairdLower Target$79.00 ➝ $73.00Low
(Data available from 4/12/2019 forward)

News Sentiment Rating

0.96 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/15/2023
  • 7 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/15/2023
  • 7 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/14/2023
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/14/2023
  • 9 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/13/2024
  • 16 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/12/2024
  • 22 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/13/2024
  • 12 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/12/2024

Current Sentiment

  • 12 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Enovis logo
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.
Read More

Today's Range

Now: $58.57
Low: $58.11
High: $59.81

50 Day Range

MA: $60.65
Low: $58.57
High: $63.80

52 Week Range

Now: $58.57
Low: $43.04
High: $66.14

Volume

342,748 shs

Average Volume

449,936 shs

Market Capitalization

$3.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.97

Frequently Asked Questions

What sell-side analysts currently cover shares of Enovis?

The following Wall Street research analysts have issued reports on Enovis in the last year: 888 Holdings plc, Canaccord Genuity Group Inc., Needham & Company LLC, Robert W. Baird, Roth Mkm, Stephens, UBS Group AG, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for ENOV.

What is the current price target for Enovis?

7 Wall Street analysts have set twelve-month price targets for Enovis in the last year. Their average twelve-month price target is $75.43, suggesting a possible upside of 28.8%. Needham & Company LLC has the highest price target set, predicting ENOV will reach $82.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $70.00 for Enovis in the next year.
View the latest price targets for ENOV.

What is the current consensus analyst rating for Enovis?

Enovis currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ENOV will outperform the market and that investors should add to their positions of Enovis.
View the latest ratings for ENOV.

What other companies compete with Enovis?

How do I contact Enovis' investor relations team?

Enovis' physical mailing address is 2711 Centerville Road Suite 400, Wilmington DE, 19808. The company's listed phone number is 302-252-9160 and its investor relations email address is [email protected]. The official website for Enovis is www.enovis.com. Learn More about contacing Enovis investor relations.